2Almasri M, Diza E, Papa A, et al. Mycoplasma pneumoniae respiratory tract infections among Greek children[J]. Hippokratia, 2011,15:147 - 152.
3Morozumi M,Takahashi T, Ubukata K. Macrolide-resistant Mycoplasma pueumoniae : characteristics of isolates and clinical aspects of communi- ty-acquired pneumonia[J]. J Infect Chemother,2010 ,16 :78 - $6.
4Bebear C, Pereyre S, Peuchant O. MycopIasma pneumoniae : susceptibi!.i- ty and resistance to antibiotics [ J ]. Future Microbiol, 2011, 6.423 -431.
5Lee PI, Wu MH, Huang LM, et al. An open, randomized, comparative study of clarithromycin and erythromycln in the treatment of children with community-acquired pneumonia [ J ]. J Microbiol Immunol Infect, 2008,41:54 -61.
6Tagliabue C, Techasaensifi C, Tones JP, et al. Efficacy of increasing dosages of clarithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia [ J ]. J Antimicrob Chemother, 2011, 66:2323 - 2329.
7Suzuki S, Yamazaki T, Narita M, et al. Clinical evaluation of macrolide- resistant Mycoplasma pneumonla [ J ]. Antimlcroh A~ents Chemothcr, 2006 ,50:7091-7092.
8Spuesens EB, Meijer A, Biersehenk D, et al. Maerolide resistance deter- mination and molecular typing of mycoplasma pneumoniae in respiratory specimens collected between 1997 and 2008 in The Netherlands [ J ]. J Clin Mierebiol,2012 ,50 : 1999 - 2004.
9Chironna M, Sallustio A, Esposito S, et al. Emergence of macrolide-re- sistant strains during an outbreak of Mycoplasma pneumoniae infections in children[J].J Antimierob Chemother,2011,66 :734 - 737.
10Bradley JS,Arguedas A, Blumer JL, et al. Comparative study of levo- floxacin in the treatment of children with community-acquired pneumo- nia [ J ]. Pediatr Infect Dis J,2007,26 : 868 - 877.
